Please join us for a discussion on what patients lives will look like in 10 years time on Friday the 16th of November in Cambridge, as part of this year’s programme of activity for Silicon Valley comes to the UK (SVC2UK).
This panel brings together a number of thought leaders from the Silicon Valley health and wellbeing Sectors and is meant to stimulate your thoughts on which successful ‘case studies’ are being run internationally in the world of medtech
Venue: Art School A Lecture Theatre, New Museums Site, University of Cambridge
Date: Friday 16 November 2012
Andy Richards (panel chair)
- George Freeman (MP)
Harpal Kumar (Crick Institute)
- Alice Rathjen (DNA Guide)
- David Levison (Cardiodx)
Ramesh Raskar (MIT MediaLab)
Stanley Yang (NeuroSky)
Moderated by acclaimed serial entrepreneur Andy Richards, we start with Harpal Kumar, the serial entrepreneur turned CEO of Cancer Research UK who talks about how the Crick Institute they are building will eradicate cancer as we know it. We then move to Ramesh Raskar who will talk about the cameras at MIT he produces which lower the cost of retinal imaging for patients from $ 2000 to $ 20. Followed up by Stanley Yang, CEO of Neurosky, the global leader in Brain-computer interface technology.
o If you are a student, we hope to help you understand why there is enormous transformative opportunity right now in health for you to join or create a company that will truly change the world as we know it,
o if you are an currently established life-science company, we hope to help you understand why this is an enormous threat to your existing business model,
o if you are an medical professional, we hope to outline how you can massively increase the impact you have with patients using modern methods.
Andy Richards. Entrepreneur and Angel Investor. Andy Richards is an Entrepreneur and Angel Investor specialising in healthcare and life sciences. He is currently Chairman of Altacor, Abcodia, Novacta and Ixico; NonExecutive Director of Summit, Arecor, PsychologyOn-line and is a special advisor to Vectura plc . In addition, he is a Non Executive Director of Cancer Research Technologies (the commercial arm of CR-UK) and Babraham Bioscience Technologies, is a member of the BBSRC Council and a Trustee of the British Science Association. He is a founder member of Cambridge Angels and an advisor to several Venture Capital Funds, Private Equity Funds and Corporate Venture Funds.
Harpal Kumar. Harpal Kumar was appointed chief executive of Cancer Research UK in 2007, having previously been its chief operating officer and chief executive of the charity’s fast-developing subsidiary Cancer Research Technology. Prior to joining Cancer Research UK he was chief executive of the disability charity the Papworth Trust and founding chief executive of Nexan Group, a venture capital-backed medical devices company. Kumar graduated from the University of Cambridge with first class honours in chemical engineering and he subsequently gained an MBA with high distinction as a Baker Scholar at Harvard Business School.
David Levison (Founder and CEO, Cardio Dx) David Levison is the Founder, Chief Executive Officer, and Director of CardioDx. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was also the interim Chief Executive Officer of XDx, Inc., a molecular diagnostic company focused on the immune system. Previously, he was the Founder, President and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark) in December 2001. Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. David also served as Chief Financial Officer of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early-stage, technology-focused venture capital firm. David received his M.B.A. from Stanford University and his B.S. from Williams College.
Ramesh Raskar is an Associate Professor at MIT and is director of the Camera Culture group at MIT Media Lab. He was a Senior Research Scientist at MERL. Before joining MIT, he invented techniques for pocket-projector based Augmented Reality as well as Computational Photography. These projects include Shader Lamps (projector-based AR), composite RFID (RFIG), multi-flash non-photorealistic camera for depth edge detection, locale-aware mobile projectors, high dynamic range video, image fusion for context enhancement and quadric transfer methods for multi-projector curved screen displays.
Alice Rathjen (CEO, DNA Guide) Alice Rathjen is the Founder and Chief Executive Officer of DNA Guide, a company making searching the genome as easy as finding a pub around the corner. In 2011 Alice won the Kaufman Business Idea Commpetition for Women in Science and Engineering. She the primary Inventor of US Patent 7089498 Method for Managing Personal Genetic Profiles. She studied ethics at UC Davis and Stanford and later received technical training in Geographic Information Systems.
Stanley Yang (CEO Neurosky). Stanley Yang is the visionary behind the bio-sensor company that has quickly become the global leader in mass market Brain-Computer Interface technology. Stanley sees the significance of the company as being “a transition in everyday life from humans conforming to machines, to machines conforming to humans”. NeuroSky adapts electroencephalography (EEG) and (since the release of blink in 2010) electromyography (EMG) technology to fit a consumer market within a number of fields such as entertainment (toys and games), education, automotive, and health.
We would be delighted if you could join us for this extremely important element of SVC2UK programme for what promises to be a stimulating and lively debate and dinner. If you should require any further information, please contact the student coordinating the event – Mansi Aggarwal. firstname.lastname@example.org
.If you would like to join the panel, please go here: http://svc2uk-medtech-panel.eventbrite.co.uk Please do not hesitate, for we are certain that this will be sold out well in advance.